Results presented at the American Association for Cancer Research Annual Meeting 2015 show the presence of a known driver of non-small cell lung cancer in small cell lung cancer, implying that promising treatments for the former may be applicable to the latter form of the disease.
Significant new treatments are available or in clinical trials for non-small cell lung cancer (NSCLC). The same explosion in treatment options is not true for the disease’s cousin, small cell lung cancer, the less common and more aggressive form of the disease. Results presented by the University of Colorado Cancer Center at the American Association for Cancer Research Annual Meeting 2015 show the presence of a known driver of NSCLC in small cell lung cancer, implying that promising treatments in development for the first may be applicable to the second form of the disease as well.
“There is an unmet need in small cell lung cancer. There have been no significant new therapies developed in 20 years,” says Fred R. Hirsch, MD, PhD, associate director for international programs at the University of Colorado Cancer Center and CEO of the International Association for the Study of Lung Cancer.
Read more at the Colorado Cancer Blogs: http://bit.ly/1cWEdEm
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Higher Life’s Essential 8 Scores Associated With Reduced COPD Risk
November 21st 2024Higher Life’s Essential 8 (LE8) scores, especially those reflecting lower nicotine exposure and better sleep health, are inversely associated with chronic obstructive pulmonary disease (COPD) risk, emphasizing the importance of cardiovascular health (CVH) in disease prevention.
Read More